Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01053988 · ClinicalTrials.gov registry record · Phase 3
A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,031
- Enrollment target
NCT01053988: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT01053988 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,031 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01053988, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,031 participants
- Enrollment target
Study Summary
The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)
Primary Outcome
Co-Primary Endpoint: Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Serial FEV1 measurements were taken electronically by spirometry at BL, weeks 2, 8, 12, and 84 (Day 168). Weighted mean (WM) was calculated using the 0 - 4 h post-dose FEV1 measurements that included the pre-dose (Day 1: 30 minutes \[min\] and 5 min prior to dosing; other serial visits:23 and 24 h
Interventions
- DRUG Placebo
- DRUG FF Inhalation Powder
- DRUG FF/GW642444 Inhalation Powder
- DRUG GW642444 Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,031 participants |
| Start Date | 2009-10-05 |
| Est. Completion | 2011-04-14 |
| Phase | Phase 3 |
What the finished NCT01053988 record still lists
NCT01053988 is an interventional study that assigns participants to a tested intervention. Its 1,031 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01053988 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01053988 about?
NCT01053988 is a clinical study titled "A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)
What is the current status of trial NCT01053988?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,031 participants. The study started on 2009-10-05. Estimated completion is 2011-04-14.
What interventions are being tested in trial NCT01053988?
The interventions under investigation include: Placebo (DRUG), FF Inhalation Powder (DRUG), FF/GW642444 Inhalation Powder (DRUG), GW642444 Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT01053988?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01053988's enrollment target sits among peer trials
1,031 288th of 2000 higher than 1,713 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07084363 · 1,032 participants · NA
Quantitative Versus qUAlitative NeuromoniToring of neUroMuscular Block for Non-cardiothoracic Surgery
- NCT06080698 · 1,030 participants · NA
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
- NCT05037682 · 1,035 participants · NA
Pain and Opioid Management in Older Adults
- NCT07282600 · 1,035 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI